Perampanel in brain tumor‐related epilepsy: Observational pilot study
Abstract Objective Possible loss of efficacy and potential interactions between antiepileptic drugs (AEDs) and chemotherapy could complicate the management of patients with brain tumor‐related epilepsy (BTRE) that may expose patients to an increased risk of adverse events. Perampanel (PER) is a high...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-06-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.1612 |
| _version_ | 1818363036467986432 |
|---|---|
| author | Marta Maschio Alessia Zarabla Andrea Maialetti Diana Giannarelli Tatiana Koudriavtseva Veronica Villani Silvana Zannino |
| author_facet | Marta Maschio Alessia Zarabla Andrea Maialetti Diana Giannarelli Tatiana Koudriavtseva Veronica Villani Silvana Zannino |
| author_sort | Marta Maschio |
| collection | DOAJ |
| description | Abstract Objective Possible loss of efficacy and potential interactions between antiepileptic drugs (AEDs) and chemotherapy could complicate the management of patients with brain tumor‐related epilepsy (BTRE) that may expose patients to an increased risk of adverse events. Perampanel (PER) is a highly selective, noncompetitive, alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid (AMPA)‐type glutamate receptor antagonist. This study evaluates the effectiveness, QoL, cognition, and mood of PER in add‐on therapy in BTRE patients. Material and Methods Observational pilot study on the effectiveness of PER as add‐on therapy in BTRE patients with uncontrolled seizures with a 6‐month follow‐up. Results We recruited 26 BTRE patients. During the follow‐up, 16 underwent chemotherapy and 11 radiotherapy; 11 had disease progression. Five patients dropped out. Mean daily PER dosage was 6.6 mg in the 21 patients who completed the follow‐up and 6.4 mg in the ITT population. The mean number of seizures/month decreased from 10.8 ± 15.03 at baseline to 1.7 ± 4.34 in the 21 patients who reached the final follow‐up. Responder rate was 88.4%: Eight patients were seizure‐free, 15 had ≥50% seizure reduction, and 3 remained stable. Four patients (15.4%) reported AEs: 2 required PER dose reduction, and 2 dropped out. Neuropsychological, mood, and QoL questionnaires were not statistically different compared to baseline. There were no significant differences in seizure control in patients with/without IDH1 mutation and with/without MGMT methylation. Conclusions Perampanel proved to be effective on seizure control in BRTE patients and to be well tolerated without negative effects on cognition and QoL. Perampanel could be a valid therapeutic option in BTRE. |
| first_indexed | 2024-12-13T21:42:05Z |
| format | Article |
| id | doaj.art-b6264a4ad7af4cf49a49d8b17ffd3054 |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-12-13T21:42:05Z |
| publishDate | 2020-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-b6264a4ad7af4cf49a49d8b17ffd30542022-12-21T23:30:30ZengWileyBrain and Behavior2162-32792020-06-01106n/an/a10.1002/brb3.1612Perampanel in brain tumor‐related epilepsy: Observational pilot studyMarta Maschio0Alessia Zarabla1Andrea Maialetti2Diana Giannarelli3Tatiana Koudriavtseva4Veronica Villani5Silvana Zannino6Regina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ Center for Tumor‐Related Epilepsy ‐ UOSD Neuroncology Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ Center for Tumor‐Related Epilepsy ‐ UOSD Neuroncology Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ Center for Tumor‐Related Epilepsy ‐ UOSD Neuroncology Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ Biostatistic Unit Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ UOSD Neuroncology Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ UOSD Neuroncology Rome ItalyRegina Elena Institute for Hospitalization and Care Scientific IRCCS ‐ UOSD Neuroncology Rome ItalyAbstract Objective Possible loss of efficacy and potential interactions between antiepileptic drugs (AEDs) and chemotherapy could complicate the management of patients with brain tumor‐related epilepsy (BTRE) that may expose patients to an increased risk of adverse events. Perampanel (PER) is a highly selective, noncompetitive, alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid (AMPA)‐type glutamate receptor antagonist. This study evaluates the effectiveness, QoL, cognition, and mood of PER in add‐on therapy in BTRE patients. Material and Methods Observational pilot study on the effectiveness of PER as add‐on therapy in BTRE patients with uncontrolled seizures with a 6‐month follow‐up. Results We recruited 26 BTRE patients. During the follow‐up, 16 underwent chemotherapy and 11 radiotherapy; 11 had disease progression. Five patients dropped out. Mean daily PER dosage was 6.6 mg in the 21 patients who completed the follow‐up and 6.4 mg in the ITT population. The mean number of seizures/month decreased from 10.8 ± 15.03 at baseline to 1.7 ± 4.34 in the 21 patients who reached the final follow‐up. Responder rate was 88.4%: Eight patients were seizure‐free, 15 had ≥50% seizure reduction, and 3 remained stable. Four patients (15.4%) reported AEs: 2 required PER dose reduction, and 2 dropped out. Neuropsychological, mood, and QoL questionnaires were not statistically different compared to baseline. There were no significant differences in seizure control in patients with/without IDH1 mutation and with/without MGMT methylation. Conclusions Perampanel proved to be effective on seizure control in BRTE patients and to be well tolerated without negative effects on cognition and QoL. Perampanel could be a valid therapeutic option in BTRE.https://doi.org/10.1002/brb3.1612antiepileptic drugsbrain tumorsBTREepilepsymolecular factorsperampanel |
| spellingShingle | Marta Maschio Alessia Zarabla Andrea Maialetti Diana Giannarelli Tatiana Koudriavtseva Veronica Villani Silvana Zannino Perampanel in brain tumor‐related epilepsy: Observational pilot study Brain and Behavior antiepileptic drugs brain tumors BTRE epilepsy molecular factors perampanel |
| title | Perampanel in brain tumor‐related epilepsy: Observational pilot study |
| title_full | Perampanel in brain tumor‐related epilepsy: Observational pilot study |
| title_fullStr | Perampanel in brain tumor‐related epilepsy: Observational pilot study |
| title_full_unstemmed | Perampanel in brain tumor‐related epilepsy: Observational pilot study |
| title_short | Perampanel in brain tumor‐related epilepsy: Observational pilot study |
| title_sort | perampanel in brain tumor related epilepsy observational pilot study |
| topic | antiepileptic drugs brain tumors BTRE epilepsy molecular factors perampanel |
| url | https://doi.org/10.1002/brb3.1612 |
| work_keys_str_mv | AT martamaschio perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT alessiazarabla perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT andreamaialetti perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT dianagiannarelli perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT tatianakoudriavtseva perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT veronicavillani perampanelinbraintumorrelatedepilepsyobservationalpilotstudy AT silvanazannino perampanelinbraintumorrelatedepilepsyobservationalpilotstudy |